Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.49 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | NOS3 | P29474 | 1/20 | 0.47 |
| ▸ | NOS1 | P29475 | 1/20 | 0.47 |
| ▸ | NOS2 | P35228 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | BRD4 | O60885 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1425282 | 0.81 | PRMT5 (0.47) | SMN1; SMN2HSD17B10PRMT5WDR77PKM | |
| SCHEMBL1425321 | 0.81 | PRMT5 (0.49) | SMN1; SMN2HSD17B10PRMT5WDR77PKM | |
| SCHEMBL3005376 | 0.81 | ESR2 (0.52) | SMN1; SMN2PRMT5WDR77MAPTALDH1A1 | |
| SCHEMBL3003136 | 0.80 | NOS3 (0.46) | SMN1; SMN2HSD17B10PRMT5WDR77PKM | |
| Hydrochloric Acid SCHEMBL9433727 | 0.80 | BRD4 (0.47) | SMN1; SMN2PRMT5WDR77TDP1ALDH1A1 | |
| SCHEMBL2992630 | 0.79 | PRMT5 (0.43) | SMN1; SMN2HSD17B10PRMT5WDR77PKM | |
| SCHEMBL1295044 | 0.79 | ALDH1A1 (0.64) | SMN1; SMN2CYP2C19MAPTABL1POLB | |
| SCHEMBL4751951 | 0.78 | HSD17B10 (0.41) | SMN1; SMN2HSD17B10PRMT5WDR77PKM | |
| SCHEMBL2995712 | 0.78 | GRM5 (0.43) | SMN1; SMN2HSD17B10PRMT5WDR77PKM | |
| SCHEMBL2999822 | 0.78 | SMN1; SMN2 (0.41) | SMN1; SMN2HSD17B10PRMT5WDR77PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10035792-B2 | Resorcinol derivative as HSP90 inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2018-07-31 | — | — | US | disclosed |
| US-10035792-B2 | Resorcinol derivative as HSP90 inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2018-07-31 | — | — | US | disclosed |
| US-10035792-B2 | Resorcinol derivative as HSP90 inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2018-07-31 | — | — | US | disclosed |
| US-20180009794-A1 | Resorcinol Derivative As HSP90 Inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2018-01-11 | — | — | US | disclosed |
| US-20180009794-A1 | Resorcinol Derivative As HSP90 Inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2018-01-11 | — | — | US | disclosed |
| EP-3248968-A1 | RESORCINOL DERIVATIVE AS HSP90 INHIBITOR | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2017-11-29 | — | — | EP | disclosed |
| EP-3248968-A1 | RESORCINOL DERIVATIVE AS HSP90 INHIBITOR | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2017-11-29 | — | — | EP | disclosed |
| WO-2016116061-A1 | RESORCINOL DERIVATIVE AS HSP90 INHIBITOR | 南京明德新药研发股份有限公司 | 2016-07-28 | — | — | WO | disclosed |
| US-9309262-B2 | Thienylindole azepines as serotonin 5-HT2C receptor ligands and uses thereof | ABT HOLDING COMPANY (US) | 2016-04-12 | — | — | US | disclosed |
| US-9309262-B2 | Thienylindole azepines as serotonin 5-HT2C receptor ligands and uses thereof | ABT HOLDING COMPANY (US) | 2016-04-12 | — | — | US | disclosed |
| EP-2004625-A2 | C-MET PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | Vertex Pharmaceuticals Incorporated (US) | 2008-12-24 | — | — | EP | disclosed |
| US-20070254868-A1 | C-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070254868-A1 | C-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070254868-A1 | C-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-11-01 | — | — | US | disclosed |
| WO-2007111904-A2 | C-MET PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-04 | — | — | WO | disclosed |
| WO-2007111904-A2 | C-MET PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-04 | — | — | WO | disclosed |
| US-20070191342-A1 | Thiophenyl and pyrrolyl azepines as serotonin 5-HT2c receptor ligands and uses thereof | ATHERSYS, INC. | 2007-08-16 | — | — | US | disclosed |
| US-20070191342-A1 | Thiophenyl and pyrrolyl azepines as serotonin 5-HT2c receptor ligands and uses thereof | ATHERSYS, INC. | 2007-08-16 | — | — | US | disclosed |
| US-20070191342-A1 | Thiophenyl and pyrrolyl azepines as serotonin 5-HT2c receptor ligands and uses thereof | ATHERSYS, INC. | 2007-08-16 | — | — | US | disclosed |
| US-20060003990-A1 | Substituted azepine derivatives as serotonin receptor modulators | ATHERSYS, INC. | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060003990-A1 | Substituted azepine derivatives as serotonin receptor modulators | HTR5A, HTR4, HTR7 | SMN1; SMN2 4252/4885HSD17B10 2187/4885PRMT5 1398/4885 |
| US-10035792-B2 | Resorcinol derivative as HSP90 inhibitor | HSP90AB1, HSP90AA1, HSP90AB2P | SMN1; SMN2 2516/4885HSD17B10 408/4885PRMT5 2620/4885 |
| US-20180009794-A1 | Resorcinol Derivative As HSP90 Inhibitor | HSP90AB1, HSP90AA1, HSP90AB2P | SMN1; SMN2 2516/4885HSD17B10 408/4885PRMT5 2620/4885 |
| US-20070191342-A1 | Thiophenyl and pyrrolyl azepines as serotonin 5-HT2c receptor ligands and uses thereof | HTR2C, HTR5A, HTR2A | SMN1; SMN2 4411/4885HSD17B10 2327/4885PRMT5 900/4885 |
| US-20070254868-A1 | C-MET protein kinase inhibitors | MET, PRKCH, ABL1 | SMN1; SMN2 1580/4885HSD17B10 4580/4885PRMT5 432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.